{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:37:37Z","timestamp":1772638657358,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing medical scientific research project","award":["2022QNXM007"],"award-info":[{"award-number":["2022QNXM007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39755-2","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:04:20Z","timestamp":1770732260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Highly sensitive profiling somatic mutations of thyroid cancer by nucleotide-enrichment-based MALDI-TOF MS assay"],"prefix":"10.1038","volume":"16","author":[{"given":"Huili","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"39755_CR1","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"39755_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato, M. et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10, 264\u2013272 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"39755_CR3","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1210\/jc.2016-1155","volume":"101","author":"HB Burch","year":"2016","unstructured":"Burch, H. B., Burman, K. D., Cooper, D. S., Hennessey, J. V. & Vietor, N. O. A 2015 survey of clinical practice patterns in the management of thyroid nodules. J. Clin. Endocrinol. Metab. 101, 2853\u20132862 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"39755_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.surg.2017.05.028","volume":"163","author":"M Bates","year":"2018","unstructured":"Bates, M. et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 163, 118\u2013123 (2018).","journal-title":"Surgery"},{"key":"39755_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.surg.2013.07.008","volume":"154","author":"RH Grogan","year":"2013","unstructured":"Grogan, R. H. et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154, 1436\u20131446 (2013).","journal-title":"Surgery"},{"key":"39755_CR6","doi-asserted-by":"publisher","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","volume":"9","author":"PC Yu","year":"2023","unstructured":"Yu, P. C. et al. TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci. Adv. 9, eadg7125 (2023).","journal-title":"Sci. Adv."},{"key":"39755_CR7","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","volume":"10","author":"SK Yoo","year":"2019","unstructured":"Yoo, S. K. et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat. Commun. 10, 2764 (2019).","journal-title":"Nat. Commun."},{"key":"39755_CR8","doi-asserted-by":"crossref","unstructured":"Haugen, B. R. et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26, 1-133 (2016). (2015).","DOI":"10.1089\/thy.2015.0020"},{"key":"39755_CR9","first-page":"1766","volume":"109","author":"AC Winters","year":"2024","unstructured":"Winters, A. C. et al. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax\/azacitidine. Haematologica 109, 1766\u20131778 (2024).","journal-title":"Haematologica"},{"key":"39755_CR10","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1038\/s41467-019-13259-2","volume":"10","author":"D Papaioannou","year":"2019","unstructured":"Papaioannou, D. et al. The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nat. Commun. 10, 5351 (2019).","journal-title":"Nat. Commun."},{"key":"39755_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","volume":"18","author":"SI Ou","year":"2023","unstructured":"Ou, S. I. et al. Distribution and detectability of EGFR exon 20 insertion variants in NSCLC. J. Thorac. Oncol. 18, 744\u2013754 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"39755_CR12","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1002\/jmv.25724","volume":"92","author":"N Akuta","year":"2020","unstructured":"Akuta, N. et al. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma. J. Med. Virol. 92, 3604\u20133608 (2020).","journal-title":"J. Med. Virol."},{"key":"39755_CR13","doi-asserted-by":"publisher","first-page":"758464","DOI":"10.3389\/fmed.2022.758464","volume":"9","author":"Y Choudhury","year":"2022","unstructured":"Choudhury, Y. et al. Complementing tissue testing with plasma mutation profiling improves therapeutic decision-making for patients with lung cancer. Front. Med. (Lausanne). 9, 758464 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"39755_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2016.07.007","volume":"49","author":"T Fleitas","year":"2016","unstructured":"Fleitas, T., Ibarrola-Villava, M., Ribas, G. & Cervantes, A. MassARRAY determination of somatic oncogenic mutations in solid tumors: moving forward to personalized medicine. Cancer Treat. Rev. 49, 57\u201364 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"39755_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00439-023-02520-w","volume":"142","author":"Q Chen","year":"2023","unstructured":"Chen, Q. et al. Target-allele-specific probe single-base extension (TASP-SBE): a novel MALDI-TOF-MS strategy for multi-variants analysis and its application in simultaneous detection of \u03b1-\/\u03b2-thalassemia mutations. Hum. Genet. 142, 445\u2013456 (2023).","journal-title":"Hum. Genet."},{"key":"39755_CR16","doi-asserted-by":"publisher","first-page":"928788","DOI":"10.3389\/fendo.2022.928788","volume":"13","author":"XQ Qian","year":"2022","unstructured":"Qian, X. Q. et al. A comparison of DP-TOF mass spectroscopy (MS) and next generation sequencing (NGS) methods for detecting molecular mutations in thyroid nodules fine needle aspiration biopsies. Front. Endocrinol. (Lausanne). 13, 928788 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"39755_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12020-017-1483-2","volume":"61","author":"C Pesenti","year":"2018","unstructured":"Pesenti, C. et al. MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay. Endocrine 61, 36\u201341 (2018).","journal-title":"Endocrine"},{"key":"39755_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-021-06364-8","volume":"190","author":"A Giannoudis","year":"2021","unstructured":"Giannoudis, A. et al. Genomic profiling using the ultraseek panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. Breast Cancer Res. Treat. 190, 241\u2013253 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"39755_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jmoldx.2018.12.001","volume":"21","author":"ES Gray","year":"2019","unstructured":"Gray, E. S. et al. Genomic analysis of Circulating tumor DNA using a melanoma-specific ultraseek oncogene panel. J. Mol. Diagn. 21, 418\u2013426 (2019).","journal-title":"J. Mol. Diagn."},{"key":"39755_CR20","doi-asserted-by":"publisher","first-page":"13390","DOI":"10.3390\/ijms241713390","volume":"24","author":"PV Leest","year":"2023","unstructured":"Leest, P. V. et al. Detection and monitoring of tumor-derived mutations in Circulating tumor DNA using the ultraseek lung panel on the massarray system in metastatic non-small cell lung cancer patients. Int. J. Mol. Sci. 24, 13390 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"39755_CR21","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1093\/nar\/gng007","volume":"31","author":"DD Giusto","year":"2003","unstructured":"Giusto, D. D. & King, G. C. Single base extension (SBE) with proofreading polymerases and phosphorothioate primers: improved fidelity in single-substrate assays. Nucleic Acids Res. 31, e7 (2003).","journal-title":"Nucleic Acids Res."},{"key":"39755_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1373\/clinchem.2008.113035","volume":"55","author":"CA Milbury","year":"2009","unstructured":"Milbury, C. A., Li, J. & Makrigiorgos, G. M. PCR-based methods for the enrichment of minority alleles and mutations. Clin. Chem. 55, 632\u2013640 (2009).","journal-title":"Clin. Chem."},{"key":"39755_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ecl.2018.11.007","volume":"48","author":"M Xing","year":"2019","unstructured":"Xing, M. Genetic-guided risk assessment and management of thyroid cancer. Endocrinol. Metab. Clin. North. Am. 48, 109\u2013124 (2019).","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"39755_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","volume":"33","author":"M Xing","year":"2015","unstructured":"Xing, M. et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol. 33, 42\u201350 (2015).","journal-title":"J. Clin. Oncol."},{"key":"39755_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl. J. Med. 368, 623\u2013632 (2013).","journal-title":"N Engl. J. Med."},{"key":"39755_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","volume":"8","author":"MM Li","year":"2020","unstructured":"Li, M. M., Maso, D. L. & Vaccarella, S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8, 468\u2013470 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"39755_CR27","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.5858\/arpa.2016-0100-RA","volume":"140","author":"M Zhang","year":"2016","unstructured":"Zhang, M. & Lin, O. Molecular testing of thyroid nodules: a review of current available tests for fine-needle aspiration specimens. Arch. Pathol. Lab. Med. 140, 1338\u20131344 (2016).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"39755_CR28","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.isci.2021.102447","volume":"24","author":"F Zhao","year":"2021","unstructured":"Zhao, F. et al. A multisite SNP genotyping and macrolide susceptibility gene method for Mycoplasma pneumoniae based on MALDI-TOF MS. iScience 24, 102447 (2021).","journal-title":"iScience"},{"key":"39755_CR29","doi-asserted-by":"publisher","first-page":"e0126721","DOI":"10.1128\/Spectrum.01267-21","volume":"9","author":"F Zhao","year":"2021","unstructured":"Zhao, F. et al. A novel strategy for the detection of SARS-CoV-2 variants based on multiplex PCR-Mass spectrometry minisequencing technology. Microbiol. Spectr. 9, e0126721 (2021).","journal-title":"Microbiol. Spectr."},{"key":"39755_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jmoldx.2022.10.004","volume":"25","author":"A Kramer","year":"2023","unstructured":"Kramer, A. et al. A micro-costing framework for Circulating tumor DNA testing in Dutch clinical practice. J. Mol. Diagn. 25, 36\u201345 (2023).","journal-title":"J. Mol. Diagn."},{"key":"39755_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"Haddad, R. I. et al. Thyroid Carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 20, 925\u2013951 (2022).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"39755_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch, Z. W. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27\u201363 (2022).","journal-title":"Endocr. Pathol."},{"key":"39755_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/thy.2016.0583","volume":"27","author":"VA Paulson","year":"2017","unstructured":"Paulson, V. A. et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features accounts for more than half of carcinomas harboring RAS mutations. Thyroid 27, 506\u2013511 (2017).","journal-title":"Thyroid"},{"key":"39755_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","volume":"95","author":"Y Cohen","year":"2003","unstructured":"Cohen, Y. et al. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95, 625\u2013627 (2003).","journal-title":"J. Natl. Cancer Inst."},{"key":"39755_CR35","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.drup.2023.101013","volume":"72","author":"H Shen","year":"2024","unstructured":"Shen, H. et al. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resist. Updat. 72, 101013 (2024).","journal-title":"Drug Resist. Updat"},{"key":"39755_CR36","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/cncr.29934","volume":"122","author":"YS Song","year":"2016","unstructured":"Song, Y. S. et al. Prognostic effects of TERT promoter mutations are enhanced by co-existence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 122, 1370\u20131379 (2016).","journal-title":"Cancer"},{"key":"39755_CR37","doi-asserted-by":"crossref","unstructured":"Lai, H. F. et al. BRAF V600E mutation lacks association with poorer clinical prognosis in papillary thyroid carcinoma. Ann. Surg. Oncol. 31 3495\u20133501 (2024).","DOI":"10.1245\/s10434-024-14935-4"},{"key":"39755_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrendo.2010.213","volume":"7","author":"P Soares","year":"2011","unstructured":"Soares, P., Sobrinho-Sim\u00f5es, M. & Cancer Small papillary thyroid cancers\u2013is BRAF of prognostic value? Nat. Rev. Endocrinol. 7, 9\u201310 (2011).","journal-title":"Nat. Rev. Endocrinol."},{"key":"39755_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000346174","volume":"1","author":"R Elisei","year":"2013","unstructured":"Elisei, R. et al. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur. Thyroid J. 1, 216\u2013231 (2013).","journal-title":"Eur. Thyroid J."},{"key":"39755_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth, L. J. et al. Efficacy of Selpercatinib in RET-altered thyroid cancers. N Engl. J. Med. 383, 825\u2013835 (2020).","journal-title":"N Engl. J. Med."},{"key":"39755_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jmoldx.2015.08.001","volume":"18","author":"MJ Mosko","year":"2016","unstructured":"Mosko, M. J. et al. Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry. J. Mol. Diagn. 18, 23\u201331 (2016).","journal-title":"J. Mol. Diagn."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39755-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39755-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39755-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:49:10Z","timestamp":1772617750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39755-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39755"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39755-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8080"}}